Navigation Links
DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
Date:1/8/2008

Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials in

2008

SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901, in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.

"This patent protection strengthens our commitment to delivering the first product to the market for the prevention of insulin-induced hypoglycemia in diabetes," CEO David Cory said. "DIO-901 is the only therapeutic in development to prevent insulin-induced hypoglycemia, which is known to limit optimal glycemic control and cause recurring medical complications in most people with type 1 diabetes, in many with type 2 diabetes, and is sometimes fatal."

Insulin-induced hypoglycemia is the limiting factor in the glycemic management of diabetes. Were it not for the barrier of hypoglycemia, people with diabetes might achieve normal HbA1c levels over a lifetime of diabetes. Reduction of mean glycemia over time prevents or delays microvascular complications -- retinopathy, nephropathy, and neuropathy -- in both type 1 and type 2 diabetes. DIO-901 is expected to begin Phase 2 clinical testing later this year and has received Fast Track status from the Food and Drug Administration, underscoring the great unmet medical need in the prevention of insulin-induced hypoglycemia.

DiObex's latest patent, U.S. Patent No. 7,314,859, builds on a growing patent portfolio protecting its product candidates for metabolic diseases. In addition to the recently issued U.S. patent, DiObex owns seven U.S. patent applications and 30 corresponding foreign patent applications relating to DIO-901. DiObex also owns or has exclusively licensed seven U.S. patents, five U.S. patent applications, and more than 100 issued foreign patents and pending foreign and international patent applications relating to DIO-902.

About DiObex

DiObex, Inc. is a privately held San Francisco-based biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin-induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and as a convenient continuous subcutaneous infusion. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
3. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
9. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
10. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
11. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... NEW YORK , January 19, 2017 ... global market for cryotherapy is set to witness a CAGR of ... North America will continue to be the leading ... ... Suppliers are emphasizing on ensuring affordable and adequate supply ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and Clinical Director of ... drug rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient ... as Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will ... version of the clinic’s leading recovery program. , “We know it’s easy ...
(Date:1/19/2017)... ... January 19, 2017 , ... In ... administered fillers that resulted in severe facial disfiguration. After four frightening years of ... doctors at UCLA Medical Center, who removed the substances in a partial facial ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced that a ... is a skilled nursing facility on the grounds of the St. Catherine’s Village campus ... was voted the best nursing home in Mississippi for the second year in a ...
Breaking Medicine News(10 mins):